Gliclazide and Aranesp drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gliclazide (gliclazide) and Aranesp (darbepoetin alfa). Common drug interactions include cardiac failure among females and dry skin among males.

The phase IV clinical study analyzes what interactions people have when they take Gliclazide and Aranesp. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.

On Jul, 10, 2026

48 people who take Gliclazide and Aranesp together, and have interactions are studied.

Gliclazide and Aranesp drug interactions.

What are the common drug interactions of Gliclazide and Aranesp, by gender? *:

female:

Cardiac failure
Cardiovascular disorder (heart diseases)
Coma (state of unconsciousness lasting more than six hours)
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
Death
Decreased appetite
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Febrile neutropenia (fever with reduced white blood cells)
Femoral neck fracture (neck of femur bone fracture)

male:

Dry skin
Anaemia (lack of blood)
Injection site pain
Injection site swelling
Mobility decreased (ability to move is reduced)
Oedema peripheral (superficial swelling)
Skin reaction
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Aplasia pure red cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells)
Dysuria (painful or difficult urination)

What are the common drug interactions of Gliclazide and Aranesp, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Dyspnoea (difficult or laboured respiration)
Fibula fracture
Malaise (a feeling of general discomfort or uneasiness)
Renal transplant
Therapeutic response decreased (less preventive response)
Tremor (trembling or shaking movements in one or more parts of your body)
Injection site pain
Injection site swelling
Mobility decreased (ability to move is reduced)
Oedema peripheral (superficial swelling)

60+:

Dry skin
General physical health deterioration (weak health status)
Anaemia (lack of blood)
Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
Cardiac failure
Death
Decreased appetite
Dyspnoea (difficult or laboured respiration)
Fall
Sepsis (a severe blood infection that can lead to organ failure and death)

What are the existing conditions these people have? *

Anaemia (lack of blood): 13 people, 27.08%
Type 2 Diabetes: 7 people, 14.58%
High Blood Pressure: 6 people, 12.50%
Constipation: 5 people, 10.42%
Multiple Myeloma (cancer of the plasma cells): 5 people, 10.42%
Folate Deficiency (lack of folic acid): 5 people, 10.42%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 4 people, 8.33%
Arrhythmias (irregular heartbeat): 4 people, 8.33%
Cardiac Failure: 4 people, 8.33%
Enlarged Prostate: 4 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and Aranesp?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously